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Abstract
Background: Post-translational modification regulates promoter-binding by Adr1, a Zn-finger transcriptional activator of
glucose-regulated genes. Support for this model includes the activation of an Adr1-dependent gene in the absence of Adr1
protein synthesis, and a requirement for the kinase Snf1 for Adr1 DNA-binding. A fusion protein with the Adr1 DNA-binding
domain and a heterologous activation domain is glucose-regulated, suggesting that the DNA binding region is the target of
regulation.
Methodology/Principal Findings: Peptide mapping identified serine 98 adjacent to the Zn-fingers as a phosphorylation
site. An antibody specific for phosphorylated serine 98 on Adr1 showed that the level of phosphorylated Adr1 relative to the
level of total Adr1 decreased with glucose derepression, in a Snf1-dependent manner. Relative phosphorylation decreased
in a PHO85 mutant, and this mutant constitutively expressed an Adr1-dependent reporter. Pho85 did not phosphorylate
Adr1 in vitro, suggesting that it affects Adr1 indirectly. Mutation of serine 98 to the phosphomimetic amino acid aspartate
reduced in vitro DNA-binding of the recombinant Adr1 DNA-binding domain. Mutation to aspartate or alanine affected
activation of a reporter by full-length Adr1, and in vivo promoter binding.
Conclusions/Significance: Mutation of Adr1 serine 98 affects in vitro and in vivo DNA binding, and phosphorylation of
serine 98 in vivo correlates with glucose availability, suggesting that Adr1 promoter-binding is regulated in part by serine 98
phosphorylation.
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Introduction
Glucose repression ensures that yeast cells use preferred carbon
sources until available supplies are exhausted. Much of the
regulation of glucose-repressed genes occurs at the level of
transcription [1,2], and in yeast, Adr1 has a pivotal role in
expressing these genes [3,4]. Control of Adr1 occurs at several
levels: through transcription of its gene [5]; post-translational
modification of the protein [6]; and access to, or ability to stably
bind promoters [7,8]. The latter two mechanisms appear to be the
most critical, because in glucose-repressed cells, raising Adr1
protein levels to be comparable to those in derepressed cells does
not activate transcription of ADH2 or other Adr1-regulated genes
[6,9]. Adr1 does not bind its cognate promoters in these
conditions, so even at elevated protein levels, post-translational
and promoter-binding regulation keep its activity in check [6,7].
Several lines of evidence suggest regulation of Adr1 binding and
activity by post-translational modification. Derepression of the
Adr1-regulated gene ADH2 can occur in the absence of protein
synthesis [6]. Snf1, a central kinase in transcription of glucose-
regulated genes, is required for Adr1 promoter-binding [7]. Snf1 is
the yeast homolog of the AMP-activated protein kinase, and
activation of Snf1 in repressing conditions relieves some glucose
repression of ADH2 and other Adr1-dependent genes, allowing up
to 10% of derepressed transcription levels [8,10]. Snf1 does not
appear, however, to phosphorylate and activate Adr1 directly, as
Adr1 lacks a consensus site for Snf1 phosphorylation and no Snf1-
Adr1 in vitro phosphorylation or association has been detected (N.
Kacherovsky, K. Dombek, unpublished). Since Snf1 is not
required for ADR1 expression [5] but is required for DNA-binding
by Adr1, one hypothesis is that Snf1 indirectly regulates Adr1 post-
translationally. Protein kinase A (PKA) has been implicated in
direct phosphorylation of Adr1. Both yeast and mammalian PKA
phosphorylate Adr1 in vitro [11], and inactivation of BCY1,
encoding the regulatory subunit of protein kinase A, inhibits Adr1
expression and activity [10,12]. Whether PKA phosphorylates
Adr1 in vivo has not been resolved, however [13]. Adr1 has a PKA
consensus site at Ser230, and mutations of this residue or in this
region lead to alleles called ADR1
c that allow constitutive ADH2
expression and hyper-derepression [11,12]. Nonetheless, the
hyper-active Adr1
c proteins are still sensitive to glucose repression
and respond to activation of Snf1 in repressing conditions,
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[8,10].
Another possible site for post-translational control of Adr1 is its
DNA binding domain (DBD, residues 76–165). Fusion of the Adr1
DBD to a heterologous activation domain confers glucose-
regulated expression on target promoters. Conversely, a Gal4
DBD - Adr1 (amino acids 21–1323) fusion shows no glucose
regulation of Gal4 targets [6]. The Adr1 DBD contains two
canonical C2H2 zinc fingers (amino acids 99–160) and an amino
terminal region of approximately 20 amino acids called PAR
(proximal accessory region) that is essential for high affinity
binding [14,15]. The structure of the DBD has been determined
by NMR in the presence and absence of DNA. The accessory
motif PAR is unstructured in the absence of DNA and assumes a
more ordered conformation when bound to DNA [16]. Mutations
in PAR affect DNA binding: changing Pro 87 or Pro 97 to Ala or
Gly abrogates DNA binding and activity in vivo [17], while
mutation of Arg 91 to Lys allows better in vitro binding and
suppresses several loss-of-function mutations in the DBD [18,19].
Because phosphorylation is a common mechanism of post-
translational modification, and the Adr1 DBD appears to be
crucial to glucose repression, we looked for phosphorylation of the
Adr1 DBD as a possible mode of regulation. Serine 98, which is in
a region critical for PAR structural changes during DNA-binding
[16], appeared to be phosphorylated in vitro and in vivo. Mutation of
serine 98 affected DNA-binding and activation of Adr1-dependent
genes, suggesting that it could play a role in glucose repression. A
screen of yeast kinase deletion mutants identified the kinase
complex Pho80/85 as affecting the phosphorylation state of Adr1
serine 98 and contributing to glucose repression of some Adr1-
dependent genes.
Results
The Adr1 DBD is phosphorylated in vitro and in vivo
Binding of DNA by Adr1 is a regulated step [7] and the DBD of
Adr1 contains a number of serine and threonine residues that
could be phosphorylated. To assess whether the Adr1 DBD might
be a target for a yeast protein kinase, we incubated recombinant
Adr1 DBD with yeast whole cell extracts and [c-32P]-ATP. SDS
gel electrophoresis followed by autoradiography showed a
prominent band at the position of the Adr1 DBD (18 kDa) that
was absent if recombinant protein was omitted from the mixture
(Figure 1A, B and Table 1 for yeast strains). N-terminal
truncations of the Adr1 DBD showed that the site of phosphor-
ylation was within amino acids 94–160, which includes the C-
terminal portion of the proximal accessory region (PAR) and the
Zn-fingers (Figure 1C, D). Two-dimensional peptide mapping and
amino acid analysis of tryptic peptides from the phosphorylated
protein (data not shown) suggested a single major site of
Figure 1. Phosphorylation of Adr1 DBD by cell extracts. A. In vitro kinase assay with purified, recombinant Adr1 DBD (amino acids 17–160 of
Adr1), [c-
32P]-ATP and cell extracts from TYY201. R, cells were grown in repressing medium; DR, cells were derepressed in 0.05% glucose for 3 hours.
Because of variability in the extracts, quantitative comparisons cannot be made between the repressed and derepressed lanes. B. Coomassie stain of
the gel in A. C. In vitro kinase assay as in A, but with N-terminally truncated versions of the Adr1 DBD. Numbers indicate the amino acid in wild-type
Adr1 that is the N-terminus of the truncated version. D. Coomassie stain of the gel in C.
doi:10.1371/journal.pone.0003213.g001
Table 1. Yeast strains
strain genotype source
BY4741 and kinase
deletions
MATa his3D1 leu2D0 met15D0 ura3D0 and
relevant gene knockout with kanMX
[43]
CKY13 MATa ade2-1 can1-100 ura3-1 leu2-3,112
trp1-1 his3-11,115 Dadr1::kanMX
this work
VBY20 MATa adh3 ura3 his3 leu2::(pRS315-ADR1)X3
ADH2::YIpADH2/lacZ(TRP1) ADH2::YIpADH2/
GFP(URA3) ADR1-3HA::kanmx
[9]
NK85 VBY20 ADR1-3HA::kanmx this work
NK87 NK85 Dsnf1::kanmx this work
NK135 NK85 Dpho85::NAT1 this work
NK136 NK85 Dpho80::NAT1 this work
NK139 NK85 Dpcl10::NAT this work
TYY201 MATa ade2 can1-100 his3-11,115 leu2-3,112
trp1-1 ura3-1
[32]
TYY497 MATa ade2 can1-100 his3-11,115 leu2-3,112
trp1-1 ura3-1 Dadr1::LEU2 ADH2::YIpADH2/
lacZ(trp1::HIS3)
[32]
doi:10.1371/journal.pone.0003213.t001
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amino acids 95–100.
To determine if serine 98 was phosphorylated in vivo, we used
antibodies raised against LRLNGRTP(pS)GKLRSFVC, where
(pS) is phosphorylated serine. Adr1 is difficult to detect in
repressed conditions, so we used strains containing a multi-copy
plasmid with ADR1 under control of the constitutive ADH1
promoter. To study the specificity of the antiserum and the effect
of point mutants that mimic the non-phosphorylated and
phosphorylated state, serine 98 on Adr1 was changed to alanine
and aspartate in related plasmids, referred to as S98A and S98D.
The anti-phosphoserine 98 peptide antiserum (a-pS98) recognized
a protein in yeast cell extracts that co-migrated with Adr1, was
absent in cells lacking Adr1 (data not shown), and was greatly
reduced when Adr1-S98A or Adr1-S98D was expressed instead of
wild-type Adr1 (Figure 2A). The specificity of a-pS98 was
confirmed when the phosphorylated peptide efficiently competed
with the protein detected on the western blot, but a non-
phosphorylated synonymous peptide did not (Figure 2B). In
summary, the serine 98 proximal to the Zn-finger domain of Adr1
is phosphorylated both in vitro and in vivo.
Adr1-Ser98 phosphorylation is affected by glucose
repression and SNF1
If phosphorylation of Adr1 at serine 98 is relevant to its activity
in vivo, we would expect the level of phosphorylation to change in
glucose derepressing conditions. We measured serine 98 phos-
phorylation in extracts from cells shifted to low glucose by western
blotting with anti-pS98 and anti-Adr1 antiserum. The intensity of
the anti-pS98 signal of each sample was normalized to its signal
with anti-Adr1. We found that derepression was accompanied by a
decrease in serine 98 phosphorylation relative to total Adr1 of five-
fold (average of three separate experiments, standard deviation of
two, Figure 2A). Glucose regulation of Adr1 occurs through SNF1
because Adr1 does not bind promoters in a Dsnf1 strain [7]. To
test the effect of Snf1 on Adr1 serine 98 phosphorylation, we used
strains with four integrated copies of ADR1 expressed from its own
promoter, one of which was tagged with a triple HA epitope.
Glucose repression is maintained in this strain despite a modestly
elevated level of Adr1 [6]. Figure 2C shows Adr1 serine 98
phosphorylation in a strain lacking Snf1. The decrease in
phosphorylation relative to total Adr1 in low glucose was less
than two-fold (average of two experiments, standard deviation of
Figure 2. In vivo phosphorylation of Adr1 at serine 98. A. Western blots with antibody against phosphorylated serine 98 of Adr1 (a-pS98) or
total Adr1 (a-Adr1 or a-HA) were performed on 50 mg of cell extract per lane from Dadr1 strain TYY497 with high-copy plasmid pNKA1 (WT, wildtype
Adr1), pNKA2 (Adr1-S98D) or pNKA4 (Adr1-S98A). Derepressed cells were grown in 0.05% glucose for one hour. B. Western blots were performed as in
A with a-pS98 or a-HA epitope antibody. Each lane contains 20 mg of repressed cell extract from TYY497 with plasmid pKD17-HA. Competing
phosphorylated (pS98)-, or non-phosphorylated Ser98 (S98)-containing peptides were added to the primary antibody at 10 mg/ml. C. Western blots
were performed as in B on 50 mg per lane of NK91. Derepressed cells were grown in 0.05% glucose, 2% ethanol for one hour. In this section, the lower
panel shows the merged images of a-pS98 and a-HA.
doi:10.1371/journal.pone.0003213.g002
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phosphorylation normally seen in low glucose.
Adr1-serine98 mutants have reduced DNA binding
affinity in vitro and in vivo
Serine 98 phosphorylation decreases in low glucose, while Adr1
promoter-binding increases, and both processes are Snf1-depen-
dent ([7], Figure 2). Therefore, we hypothesized that the DNA-
binding of Adr1 would be affected by its serine 98 phosphorylation
state. In support of this hypothesis, serine 98 is in a region
previously shown to be important for DNA binding, the PAR
adjacent to the Zn-finger domain [15,16,20]. The DNA binding
affinity for recombinant proteins from the wild-type, S98A and
S98D plasmids were measured using an electrophoretic mobility
shift assay (EMSA). Figure 3 shows that the neutral S98A mutation
did not affect in vitro DNA binding, but the phosphomimetic S98D
mutation reduced DNA binding affinity approximately 10-fold.
The apparent equilibrium constant of Adr1-S98D was 200nM
compared to about 20nM for the wild-type and S98A mutant
proteins. Other mutations in PAR, such as at proline 97, similarly
reduced DNA binding affinity in vitro [20].
Chromatin immunoprecipitation (ChIP) analysis with quantita-
tion by real-time PCR (qPCR) was used to compare in vivo
promoter-binding of wild-type Adr1 and the S98 mutants. As
expected, binding of the Adr1-S98D mutant was at or below
background levels, even when over-expressed from a 2m plasmid
under ADH1 promoter-control (data not shown). The Adr1-S98A
mutant, however, gave unexpected results. When expressed from a
CEN plasmid to ensure physiological levels, binding of the S98A
mutant was reduced strongly at ADH2 compared to wildtype Adr1
(Figure 4). Binding was also assayed at POX1, ATO3 and ADY2,
which are all highly glucose-repressed, strongly Adr1-dependent
for expression, and have promoters that are bound by Adr1.
ADH2, ADY2 and ATO3 are Snf1-dependent, but POX1 is not
[4,21]. Binding of the S98A mutant was as strongly affected at
POX1 as it was at ADH2, and was significantly decreased at ATO3.
In summary, mutation of Adr1 serine 98 to the phosphomimetic
amino acid aspartate reduced DNA binding affinity in vitro and led
to loss of in vivo binding detection. Mutation to alanine did not
affect in vitro DNA binding, but reduced in vivo binding.
Mutation of Adr1-Ser98 to Asp or Ala decreases
transcription activation
Since mutation of serine 98 affected the ability of Adr1 to bind
promoters, we tested the effect on activation of glucose-repressed
genes. First, a yeast strain lacking Adr1 was transformed with multi-
copy plasmids expressing wild-type Adr1, Adr1-S98A or Adr1-S98D
under the control of the ADH1 promoter. The activity of over-
expressed Adr1 was assayed using an Adr1-responsive integrated
ADH2/lacZ reporter gene. Wild-type Adr1 was active in both
repressing and derepressing medium as expected, because over-
expression of Adr1 to thislevel overcomes glucose repression ([22,23],
Figure 3. In vitro binding of Adr1DBD and Ser98 mutants. A. Electrophoretic mobility shift assays (EMSA) were performed with increasing
amounts of Adr1 DBD (amino acids 17–160) and its Ser98Ala (S98A) and Ser98Asp (S98D) variants, against a fluorescently labeled double-stranded
oligonucleotide containing the Adr1 binding site (UAS1) from the ADH2 promoter. Blue line, wildtype; red line S98A; green line S98D. Error bars
represent the standard deviation of the mean measured in duplicate experiments. B. EMSA gel showing mobility shifts of the ADH2 promoter probe
with wildtype Adr1 DBD or the S98D mutant.
doi:10.1371/journal.pone.0003213.g003
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very low activity in both repressing and derepressing conditions. The
S98A mutant was slightly less active than the wild-type protein.
Western blots for Adr1-HA protein showed similar levels of wild-type
and mutant proteins, indicating that the inactivity of Adr1-S98D was
not due to poor expression or instability (data not shown).
Some ADH2 expression was seen in a strain with the Adr1-S98A
mutant, in contrast to the Adr1-S98D mutant strain, which had
less than 10% of wildtype expression levels. To examine the Adr1-
S98A mutant at physiological levels, the S98A mutant allele was
transferred to a CEN plasmid and expressed under the control of
its own promoter. The defective transcription activation of this
mutant was confirmed and extended to other Adr1-dependent
genes by measuring RNA levels with quantitative real-time PCR
(Figure 5). ADH2 expression was reduced 5-fold. Expression of the
Adr1-dependent gene POX1 was reduced 2.9-fold. Two other
Adr1-dependent genes, ATO3 and ADY2 were activated equally
well by mutant and wild-type Adr1, consistent with the higher
level of in vivo Adr1-binding at these promoters (Figure 4).
Pho85 is involved in Adr1-Ser98 phosphorylation
Binding and gene expression data showed that serine 98,
proximal to the Zn-finger domains, is important for the function of
Adr1. Since its phosphorylation state correlated with glucose
availability, we identified potential kinases by screening for Adr1-
phosphoserine 98 in a collection of 102 yeast strains, each deleted
for a gene encoding a non-essential kinase. Each kinase mutant
was transformed with a multi-copy plasmid expressing Adr1 from
the ADH1 promoter. Phosphorylation of serine 98 was measured
and normalized to total Adr1 using immunoprecipitation with
anti-Adr1 antiserum followed by western blotting with either anti-
pS98 or anti-Adr1 antiserum. Figure 6 shows the screening of a
subset of mutants by western blot. For the wild-type strain, the
signal ratio for the two antibodies was 0.17 (+/2 0.04, for three
independent cultures). Three kinase mutations showed altered
levels of serine 98 phosphorylation: pho85 (signal ratio 0.08), dun1
(0.27), and ssk2 (0.11). We focused on pho85 since it has been
reported to have a role in growth control at the diauxic transition
[24]. Dun1 is important for DNA damage control [25] and Ssk2 is
involved in responding to osmotic stress [26]. Adr1 has not been
implicated in either of these processes.
Pho85 is a cyclin-dependent protein kinase with multiple cyclin
partners [27]. Yeast strains with deletions in genes encoding
Pho85-associated cyclins were taken from the yeast deletion
collection and transformed with the multi-copy ADH1 promoter-
ADR1 plasmid. Screening by ADHII activity assays [28] and
Western blotting as described above, indicated that Pho80 might
affect Adr1 phosphorylation and Adr1-dependent gene expression
(data not shown). We then tested the effects of deleting the genes
for the PHO85 kinase, its cyclin partner PHO80 and two cyclins
Figure 4. In vivo binding of Adr1 and S98A mutant. Chromatin
immunoprecipitation assays were performed using anti-HA antibody on
the Dadr1 strain TYY497 with pKD16-HA (wildtype, HA-tagged Adr1,
black bars) and pKD16-9-HA (Ser98Ala, HA-tagged Adr1, gray bars)
derepressed in 0.05% glucose for 3 hours. Quantitation was performed
by RTqPCR for the indicated promoters normalized to a non-Adr1-
bound telomeric region. Error bars are the standard deviation for the
average of technical replicates.
doi:10.1371/journal.pone.0003213.g004
Table 2. Beta-galactosidase assays on ADH2 promoter-lacZ
with high-copy ADR1 wildtype or S98 mutants
strain
a ß-galactosidase activity (Miller Units)
Adr1 R
b DR
WT 340 (50)
c 630 (170)
S98A 260 (47) 290 (100)
S98D 6 (0.1) 30 (3.0)
aTYY497 with pNKA1, pNKA2 or pNKA4
bR, repressed; DR, derepressed 0.05% glucose 2% ethanol, 2 hours
cNumbers in parentheses are standard deviations for the average of three
independent cultures
doi:10.1371/journal.pone.0003213.t002
Figure 5. Activation of Adr1-dependent genes by Adr1 or the
S98A mutant. RTqPCR on RNA isolated from Dadr1 strain CKY13 with
pKD16-HA (wildtype, HA-taggedAdr1, black bars) andpKD16-HA-9(S98A,
HA-tagged Adr1, gray bars) derepressed in 0.05% glucose for 3 hours.
Quantitation was for the indicated genes normalized to ACT1. Error bars
are the standard deviation for the average of technical replicates.
doi:10.1371/journal.pone.0003213.g005
Figure 6. Effect of Dpho85 on Adr1 phosphorylation. Western
blots using antibody against phosphorylated serine 98 of Adr1 (a-pS98)
or total Adr1 (a-Adr1) were performed on 99–125 mg of cell extract per
lane from BY4741 wildtype or strains with the indicated kinase gene
deletion. Each strain carried the high-copy Adr1 plasmid pNKA1-U.
doi:10.1371/journal.pone.0003213.g006
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activation by Adr1. Strains containing an ADH2 promoter/lacZ
reporter and four integrated copies of ADR1 [6], were deleted for
PHO85 or Pho85-associated cyclin genes. PHO85 and PHO80, but
not PCL6 or PCL10 affected ADH2-lacZ expression by beta-
galactosidase assays in repressed conditions and blue/white color
on X-gal-glucose plates (Table 3 and data not shown).
To test for direct phosphorylation of the Adr1-DBD by Pho80/
85, in vitro kinase assays [29] were performed with purified Pho80/
85 complex (a gift from Ian Carter-O’Connell from Erin O’Shea’s
lab) on purified recombinant Adr1 DBD, or the unphosphorylated
17-amino acid serine 98-containing peptide that was generated for
affinity purification of a-pS98. We could not detect phosphory-
lation of the Adr1 DBD with the purified kinase-cyclin. We assume
the effect of PHO85 on Adr1 phosphorylation that is seen in
Figure 6 is indirect, since purified Pho80/85 could phosphorylate
a purified Pho4 control, but did not phosphorylate the Adr1 DBD
or the serine 98-containing peptide (data not shown).
Discussion
Serine 98 of Adr1 is involved in regulation of DNA-
binding
Adr1 directly regulates at least 30 glucose-repressed genes [4,21]
and is itselfregulated at the level of DNA-binding [7]. We found that
mutation of serine 98 in the PAR region of Adr1, which is crucial for
optimal binding [15,16,20,30], had a severe effect on in vivo binding
to, and activation of the ADH2 promoter. Mutation to the
phosphomimetic amino acid aspartate had more deleterious effects
than mutation to alanine on both in vitro binding and activation,
suggesting that phosphorylation of serine 98 might have similar
consequences. The effect of the alanine mutation on Adr1-
dependent genes ranged from 5-fold or greater decreases in binding
and activation (ADH2), to no effect (ADY2). This may reflect
differences in the structure and coactivator requirements of the
different promoters, which we find leads to measurable differences in
the DNA binding or activator function of Adr1 [31]. Serine 98 is
adjacent to the proline at position 97 that creates a turn in the
structure of the DBD [16], which may explain why even mutation to
a neutral amino acid affects activator function. Serine 98 was
phosphorylated in vivo, and phosphorylation was affected by both
glucose availability and Snf1. SNF1 was required for the decrease in
phosphorylation in response to derepressing conditions.
Several possible mechanisms could explain how post-transla-
tional modification of Adr1 may regulate promoter binding and
transcription activation. Adr1 promoter-binding may be stabilized
by interactions with coactivators [32], and post-translational
modification may regulate this interaction. A plausible hypothesis
is that phosphorylation interferes with coactivator interaction.
However, the close proximity of serine 98 to the DBD of Adr1
(Figure 7) decreases the likelihood of direct coactivator binding. In
addition, the Adr1 DBD binds DNA in absence of coactivators in
the in vitro EMSA assay, suggesting a reasonably stable binding
without assistance. Another candidate for regulating interaction
with stabilizing coactivators is serine 230 on Adr1. This residue
also appears to be phosphorylated, with relative levels of
phosphorylation changing in derepression (S. Ratnakumar and
N. Kacherovsky, unpublished). Since this residue is far from the
DNA-binding domain, it is a better candidate for regulating
interactions with coactivators. Since serine 98 is in a region known
to be important for DNA-binding, and mutation affects binding in
vivo and in vitro, we propose that phosphorylation of this residue
directly affects Adr1-DNA interactions. A model of the Adr1 DBD
binding to DNA based on nuclear magnetic resonance spectros-
copy of the complex in solution, shows the serine 98 in a position
to influence interactions between the PAR domain and DNA.
(Figure 7). Since mutation of serine 98 affects binding in vivo and in
vitro, our current working hypothesis is that phosphorylation of this
residue affects Adr1-DNA interactions.
In vivo evidence suggested the Pho80/85 kinase/cyclin complex
contributed to phosphorylation of Adr1 at serine 98; however, in
vitro evidence suggested the effect was indirect, and serine 98 is not
within a Pho85 consensus sequence [33]. We had observed that
the Dpho85 strain with the high-copy ADR1 plasmid grew
approximately 75% slower than a PHO85 strain carrying the
same plasmid, suggesting a physiologically relevant interaction
between Pho85 and Adr1. The slower growth rate was partially
because of the pho85 mutation, but the growth rate of the Dpho85
strain with the high-copy ADR1-S98D plasmid was only 19%
slower than the comparable PHO85 strain. The synthetic
deleterious effect between high-copy ADR1 and Dpho85, with
partial rescue by mutation of the phosphorylatable residue on
Adr1 suggests a common pathway. Pho85 involvement in Adr1
regulation was also observed in a gene expression microarray
performed in a Dpho85 strain undergoing the diauxic transition
[24]. Many Adr1-dependent genes were characterized as having
elevated expression in the pho85 mutant before the cells had
exhausted their supply of glucose. Pho85, paired with the cyclin
subunits Pcl8 and Pcl10, is involved in glycogen synthesis, in the
same pathway as Snf1 [34], and a pho85 mutant has growth defects
on non-glucose carbon sources [35]. Here we present data that
support a function for Pho85 in glucose repression.
Materials and Methods
Strains and plasmids
Yeast strains are listed in Table 1. Epitope-tagging was as
described in Knop et al. [36] and gene deletion was as described in
Gu ¨ldener et al. [37].
Cells were grown as described in Sherman [38]. For glucose
repression, medium contained 5% glucose; for derepression,
0.05% glucose with or without 2% ethanol.
Plasmid pF1F2 (Adr1 17–160 a.a.) [15] was used to express the
Adr1 DBD in E. coli for purification. Plasmids F1F2S98A and
F1F2S98D were generated from pF1F2 using the Stratagene
QuickChange kit. pNKA1, pNKA2, pNKA4, which have the
genes for wildtype, S98D and S98A Adr1 DBD, respectively, were
made by GAP repair [39] using PCR fragments generated from
pF1F2, pF1F2S98D, and pF1F2S98A, cotransformed into yeast
with linearized pKD46, which has ADR1 under control of the
ADH1 promoter, on a 2m-TRP1 plasmid (K. Dombek, unpub-
lished). pNKA1-U is pNKA1 with the TRP1 marker swapped for
Table 3. Beta-galactosidase assays with ADH2 promoter-lacZ
in Dpho80, Dpho85, Dpcl10
strain
a ß-galactosidase activity (Miller Units)
WT 5.3 (1.7)
b
Dpho85 180 (103)
Dpho80 28 (1.1)
Dpcl10 2.6 (0.8)
aNK85, NK135, NK136 or NK139 grown in YPD 5% glucose
bNumbers in parentheses are standard deviations for the average of duplicate
cultures
doi:10.1371/journal.pone.0003213.t003
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pKD16 and pKD17 [5] tagged as described in Knop et al. [36].
The Serine 98 in pKD16-HA-9 was mutated to alanine using the
QuickChange kit (Stratagene).
In vitro phosphorylation of Adr1
Purification of Adr1 DBD (F1F2) or the S98A or S98D variants
from E. coli was as described in Young et al. [4] from pF1F2,
F1F2S98A or F1F2S98D. For in vitro phosphorylation of the Adr1
DBD, 1–10 mg of Adr1F1F2 was bound to Ni-NTA magnetic
agarose beads (Qiagen) through its His6 tag, and resuspended in
kinase buffer (10mM Tris pH 7.5, 10mM MgCl2, 20mM beta-
mercaptoethanolor10mMdithiothreitol,0.005%Tween20,10mM
imidazole, 2mM ATP, 1–5 mCi per reaction of 3000Ci/mmol
[c-
32P]-ATP). An equal volume of cell extract made according to
Thukral et al. [30] was added, and after 15–60 minutes at 37uC, the
reaction was stopped by washing the beads four times in 10mM Tris
pH 8.0, 300mM NaCl, 10mM imidazole, 0.005% Tween 20. Adr1
DBD was eluted by boiling in 46LDS loading buffer (Invitrogen),
run on a 12% gel (Invitrogen) with protein standards, and visualized
with a Storm Phosphorimager. Yeast protease inhibitor cocktail
(Sigma), 1mM PMSF, and phosphatase inhibitors (1 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 mM ß-glycero-
phosphate, 1 mM EGTA and 10 mM sodium fluoride), were added
to extracts and wash buffers.
Tryptic peptide mapping and phosphoamino acid analysis were
performed as described in Boyle et al. [41] using Adr1 DBD
phosphorylated as for the in vitro phosphorylation by cell extracts.
The Pepsort program http://pingu.salk.edu/,sefton/Hyper_
protocols/pepsort1.html generated the graph with predicted
tryptic peptide electrophoretic patterns.
In vivo phosphorylation of Adr1
Gel electrophoresis and Western blots were carried out on yeast
extracts generated according to Horvath and Reizman [42] and
Hahn, S ‘‘Rapid yeast protein prep for SDS PAGE and Western,’’
http://www.fhcrc.org/science/labs/hahn/methods/biochem_meth/
yeast_prot_SDS.html with addition of a 30 second bead-beating
step before boiling. Tris-Acetate 3–8% gels were run, Western
blotted, visualized and quantitated according to manufacturer’s
instructions for the NuPage system (Invitrogen) and Odyssey
Infrared imaging system (Licor Biosciences). Polyclonal primary
antibodies were used at 1:500–1:1000 and were anti-HA (Y-11,
Santa Cruz Biochemicals), anti-Adr1 [10] or antibodies against
phosphoserine 98 of Adr1. For the latter, the peptide
LRLNGRTP(pS) GKLRSFVC and its unphosphorylated version
were synthesized and used to generate and affinity purify the anti-
pS98 antibody by Bethyl Laboratories (Montgomery, TX).
Secondary IR-dye conjugated antibodies used at 1:1000–1:3000
were goat anti-mouse Alexa 680 (Molecular Probes) or IRdye800
conjugated anti-rabbit IgG (Rockland Immunochemicals).
The screen for yeast mutants that affected Adr1 phosphorylation
used a subset of 102 strains from the MATa yeast gene deletion
collection (Invitrogen) that encode protein kinases according to the
Saccharomyces Genome Database (yeastgenome.org). Strains were
transformed with pNKA1-U. After growth under glucose repressing
conditions, cell extracts were made by bead beating in lysis buffer
(50mM Hepes pH 7.5, 140 mM NaCl, 1% Triton X-100, 0.1%
Figure 7. Model of the Adr1 DBD - DNA interaction, showing the position of serine 98. A model of the Adr1 PAR and DBD (ribbon
structure) bound to its recognition sequence in DNA (space-filling model), based on NMR spectra of the complex in solution. Fingers 1 and 2 are the
Zn-fingers; P87 and P97 are prolines; the arrow points to serine 98. Reprinted by permission from Macmillan Publishers Ltd: Nat Struct Biol 6:478–485,
copyright 1999.
doi:10.1371/journal.pone.0003213.g007
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described above). After centrifugation, protein concentration was
determined with the Bio-Rad protein assay kit, and 1 mg of soluble
extract was incubated with 5–10 ml anti-Adr1 antibody [10] for
3h o u r sa t4 uC. After centrifugation, the supernatant was transferred
to a tube with 60 ml of a 1:1 suspension of protein A sepharose : PBS
(GE Healthcare) and incubated on a rocking platform for 1 hour,
4uC. After 3 washes with lysis buffer, Adr1 was eluted with 60 ml4 6
LDSsamplebuffer(Invitrogen)at70uCfor10 minutesand analyzed
by Western blot with as described above.
Expression of Adr1-dependent genes and Adr1 DNA
binding
RNA expression and ADH2 promoter - lacZ reporter activity
was measured as described in Tachibana et al. [8]. ChIP assays
were performed as described in Young et al. [4]. The sequences of
oligonucleotides used for cloning and diagnostics are available on
request.
Electrophoretic Mobility Shift Assays (EMSA)
EMSA was conducted as in Thukral et al. [17], using a double-
stranded probe containing the UAS1 sequence (underlined) from
the ADH2 promoter (sequence of top strand: 59 GCA TTG ACT
AAG TTC TCC AAC TTA TAA GTT GGA GAT GAA TCA
GTT ACG 39) labeled with an infrared dye and quantitated with
an Odyssey Infrared Imaging System (Li-Cor Biosciences). Signals
from all shifted bands in a lane were divided by the combined
signal for all bands in the lane to determine % bound.
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